HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Spetz, A.-L. Articles by Hinkula, J. Search for Related Content PubMed PubMed Citation Articles by Spetz, A.-L. Articles by Hinkula, J.

Induction of HIV-1-Specific Immunity After Vaccination with Apoptotic HIV-1/Murine Leukemia Virus-Infected Cells¹

Anna-Lena Spetz^2,*, Anna Smed Sörensen^*, Lilian Walther-Jallow^*, Britta Wahren^,, Jan Andersson^*, Lars Holmgren and Jorma Hinkula^,,¶

^* Department of Medicine, Center for Infectious Medicine, Huddinge University Hospital, and Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, Sweden; Swedish Institute for Infectious Disease Control, Stockholm, Sweden; Cancer Center, Karolinska Hospital, Karolinska Institutet, Stockholm, Sweden; and ^¶ Department of Health and Society, Malmö University, Malmö, Sweden

Ag-presenting dendritic cells present viral Ags to T cells after uptake of apoptotic bodies derived from virus-infected cells in vitro. However, it is unclear whether apoptotic virus-infected cells are capable of generating immunity in vivo. In this study, we show that inoculation of mice with apoptotic HIV-1/murine leukemia virus (MuLV)-infected cells induces HIV-1-specific immunity. Immunization with apoptotic HIV-1/MuLV-infected syngeneic splenocytes resulted in strong Nef-specific CD8⁺ T cell proliferation and p24-induced CD4⁺ and CD8⁺ T cell proliferation as well as IFN- production. In addition, systemic IgG and IgA as well as mucosa-associated IgA responses were generated. Moreover, mice vaccinated with apoptotic HIV-1/MuLV cells were protected against challenge with live HIV-1/MuLV-infected cells, whereas mice vaccinated with apoptotic noninfected or MuLV-infected splenocytes remained susceptible to HIV-1/MuLV. These data show that i.p. immunization with apoptotic HIV-1-infected cells induces high levels of HIV-1-specific systemic immunity, primes for mucosal immunity, and induces protection against challenge with live HIV-1-infected cells in mice. These findings may have implications for the development of therapeutic and prophylactic HIV-1 vaccines.

This article has been cited by other articles:

				U. Johansson, L. Walther-Jallow, A. Smed-Sorensen, and A.-L. Spetz Triggering of Dendritic Cell Responses after Exposure to Activated, but Not Resting, Apoptotic PBMCs J. Immunol., August 1, 2007; 179(3): 1711 - 1720. [Abstract] [Full Text] [PDF]

				J. J. Donnelly, B. Wahren, and M. A. Liu DNA Vaccines: Progress and Challenges J. Immunol., July 15, 2005; 175(2): 633 - 639. [Abstract] [Full Text] [PDF]